Literature DB >> 22681673

Hepatocellular carcinoma and gastroenteropancreatic neuroendocrine tumors: potential role of other positron emission tomography radiotracers.

Hossein Jadvar1.   

Abstract

18F-Fluorodeoxyglucose avidity for gastroenteropancreatic neuroendocrine tumors and hepatocellular carcinoma is variable, depending on the underlying tumor biology. Experience with non-fluorodeoxyglucose (FDG) tracers (eg, 18F-labeled amine precursors l-dihydroxyphenylalanine and 68Ga-DOTA-peptides for gastroenteropancreatic neuroendocrine tumors and radiolabeled acetate or choline for hepatocellular carcinoma) is evolving and expanding rapidly. This article reviews the role of FDG and non-FDG radiotracers in the imaging evaluation of patients with gastroenteropancreatic neuroendocrine tumors or hepatocellular carcinoma.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22681673     DOI： 10.1053/j.semnuclmed.2012.02.001

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN： 0001-2998            Impact factor:   4.446


  9 in total

Review 1.  Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation.

Authors:  Umberto Cillo; Tommaso Giuliani; Marina Polacco; Luz Maria Herrero Manley; Gino Crivellari; Alessandro Vitale
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

2.  Fluorine-18 Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma: Correlation with Glucose Transporters and p53 Expression.

Authors:  Ana F Brito; Ana M Abrantes; Marina Ribeiro; Rui Oliveira; João Casalta-Lopes; Ana C Gonçalves; Ana B Sarmento-Ribeiro; José G Tralhão; Maria F Botelho
Journal:  J Clin Exp Hepatol       Date:  2015-06-03

Review 3.  Competitive advantage of PET/MRI.

Authors:  Hossein Jadvar; Patrick M Colletti
Journal:  Eur J Radiol       Date:  2013-06-18       Impact factor: 3.528

Review 4.  Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2017-05-02       Impact factor: 3.959

5.  Diagnostic role of radiolabelled choline PET or PET/CT in hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Francesco Bertagna; Mattia Bertoli; Giovanni Bosio; Giorgio Biasiotto; Ramin Sadeghi; Raffaele Giubbini; Giorgio Treglia
Journal:  Hepatol Int       Date:  2014-09-03       Impact factor: 6.047

6.  Utility of [18F]FSPG PET to Image Hepatocellular Carcinoma: First Clinical Evaluation in a US Population.

Authors:  Gina Kavanaugh; Jason Williams; Andrew Scott Morris; Michael L Nickels; Ronald Walker; Norman Koglin; Andrew W Stephens; M Kay Washington; Sunil K Geevarghese; Qi Liu; Dan Ayers; Yu Shyr; H Charles Manning
Journal:  Mol Imaging Biol       Date:  2016-12       Impact factor: 3.488

7.  68Ga-PSMA PET/CT Versus 18F-FDG PET/CT for Imaging of Hepatocellular Carcinoma

Authors:  Cihan Gündoğan; Nurhan Ergül; Mehmet Semih Çakır; Özgür Kılıçkesmez; Rıza Umar Gürsu; Tamer Aksoy; Tevfik Fikret Çermik
Journal:  Mol Imaging Radionucl Ther       Date:  2021-06-03

Review 8.  6-[18F]fluoro-L-DOPA: a well-established neurotracer with expanding application spectrum and strongly improved radiosyntheses.

Authors:  M Pretze; C Wängler; B Wängler
Journal:  Biomed Res Int       Date:  2014-05-28       Impact factor: 3.411

9.  Role of imaging in management of hepatocellular carcinoma: surveillance, diagnosis, and treatment response.

Authors:  Azeez Osho; Nicole E Rich; Amit G Singal
Journal:  Hepatoma Res       Date:  2020-08-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.